Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma

• Published in: BMC medical genomics Vol. 17; no. 1; pp. 265 - 18
• Main Authors: Gu, Huiquan, Gao, Xinzheng, Han, Wenlong, Wang, Fangyu, Zhang, Hanqiang, Yao, Longyu, Chen, Weimin, Liu, Qiang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.11.2024; BioMed Central; BMC
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - metabolism; Adenocarcinoma of Lung - pathology; Aged; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic drugs; Biomarker; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer; Cancer therapies; CDCA8; Cell cycle; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell division; Datasets; Diagnosis; Drug development; Drug resistance; Drug Resistance, Neoplasm - genetics; Drug therapy; Female; Gene expression; Gene Expression Regulation, Neoplastic; Gene silencing; Genes; Genetic aspects; Helper cells; Humans; Immunohistochemistry; Immunosuppressive agents; Infiltration; Leukocytes (eosinophilic); LUAD; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Lymphocytes T; Male; Mast cells; Medical prognosis; Metastases; Middle Aged; Nomograms; Oncology, Experimental; p53 Protein; Patients; Prognosis; Proteins; Regression analysis; RNA-mediated interference; Sensitivity; Sensitivity analysis; Stem cells; Survival analysis; Tumors; China; CDCA8; Biomarker; Sensitivity; Prognosis; LUAD

Lung adenocarcinoma (LUAD) accounts for the highest proportion of lung cancers; however, specific biomarkers are lacking for diagnosis, treatment, and prognostic assessment. Cell division cycle-associated 8 (CDCA8) is a cell cycle regulator with elevated expression in various cancers. However, the a...